Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc

Registered Charity 3104


Mailing address:

PO Box 322,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (PDF, 156KB)
Why become a member?

Pfizer cancels development of two late-stage drugs

Tuesday 3 March 2009

Tablets Reuters reports that drug company Pfizer has put a halt to the development of two drugs that were specifically aimed at treating Fibromyalgia and anxiety:

“Pfizer Inc (PFE.N) said it is dropping two drugs in late-stage development -- one for anxiety and one for fibromyalgia -- after data showed they would not work much better than existing treatments.

The dropped drugs are the latest casualties of the No. 1 drugmaker's sputtering research engine. Earlier this year the company halted a late-stage trial of a drug that failed to improve survival in pancreatic cancer patients and last year it dropped a late-stage obesity drug.

"This is just another sign that Pfizer's research and development operation is not as effective as it needs to be," said David Moskowitz, an analyst at Caris & Co. "If they are killing projects like this in Phase II, it is understandable. If they are killing them in Phase III, they need to go back and look at their decision process.".”

The full article is here:

Reuters: Pfizer cancels development of two late-stage drugs



blog comments powered by Disqus
Previous Previous Page